- Home
- ANEB vs IMUX Comparison
ANEB vs IMUX Comparison
Compare ANEB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- IMUX
- Stock Information
- Founded
- ANEB 2020
- IMUX 2016
- Country
- ANEB United States
- IMUX United States
- Employees
- ANEB N/A
- IMUX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- IMUX Health Care
- Exchange
- ANEB Nasdaq
- IMUX Nasdaq
- Market Cap
- ANEB 111.8M
- IMUX 92.2M
- IPO Year
- ANEB 2021
- IMUX N/A
- Fundamental
- Price
- ANEB $2.27
- IMUX $0.75
- Analyst Decision
- ANEB Buy
- IMUX Strong Buy
- Analyst Count
- ANEB 2
- IMUX 5
- Target Price
- ANEB $8.00
- IMUX $6.00
- AVG Volume (30 Days)
- ANEB 17.9K
- IMUX 1.3M
- Earning Date
- ANEB 11-13-2025
- IMUX 11-13-2025
- Dividend Yield
- ANEB N/A
- IMUX N/A
- EPS Growth
- ANEB N/A
- IMUX N/A
- EPS
- ANEB N/A
- IMUX N/A
- Revenue
- ANEB N/A
- IMUX N/A
- Revenue This Year
- ANEB N/A
- IMUX N/A
- Revenue Next Year
- ANEB N/A
- IMUX N/A
- P/E Ratio
- ANEB N/A
- IMUX N/A
- Revenue Growth
- ANEB N/A
- IMUX N/A
- 52 Week Low
- ANEB $0.80
- IMUX $0.56
- 52 Week High
- ANEB $3.42
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- ANEB 33.07
- IMUX 46.20
- Support Level
- ANEB $2.32
- IMUX $0.67
- Resistance Level
- ANEB $2.39
- IMUX $0.79
- Average True Range (ATR)
- ANEB 0.09
- IMUX 0.05
- MACD
- ANEB -0.04
- IMUX 0.00
- Stochastic Oscillator
- ANEB 0.00
- IMUX 49.09
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.